Pomalidomide and lenalidomide regulate erythropoiesis and fetal hemoglobin production in human CD34⁺ cells
J. Clin. Invest. Laure A. Moutouh-de Parseval, et al. 118:248 doi:10.1172/JCI32322 [Go to this article.]

Figure 2
Pomalidomide and lenalidomide increase HbF production in erythroid cells. (A) Quantification of total Hb production was done by ELISA assay after 6 days of erythroid differentiation. Values represent mean ± SEM (n = 3). (B) Expression of HbF was monitored by flow cytometry after 2, 6, 9, and 12 days of cell differentiation with 1 μM pomalidomide. (C and D) HbF and HbA were monitored after 6 days of cell differentiation, with increasing concentrations of pomalidomide. Scatter plots illustrate the distribution of HbF⁺ and HbA⁺ erythroid cells. The experiments were repeated on samples from at least 2 different donors with similar results. *P < 0.05.